Advertisement
Canada markets closed
  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • Bitcoin CAD

    88,324.34
    +2,868.93 (+3.36%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     
  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

RDInvesting Provides Investors with Free In-Depth Equity Reports on ANGI, FOLD, MCRL and WILN

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

Angie's List Inc. (NASDAQ:ANGI - News) shares declined 8.40 percent to close at $13.41 a share Friday. The stock traded between $13.23 and $14.71 on volume of 4.11 million shares traded. Analysts at B. Riley have recently downgraded the company’s rating to "neutral" from "buy". Shares of Angie's List have gained approximately 12.0 percent year-to-date.

Find out more about Angie's List including full access to the free equity report at:
www.RDInvesting.com/ANGI

Amicus Therapeutics, Inc. (NASDAQ:FOLD - News) shares declined 2.58 percent to close at $2.27 a share Friday. The stock traded between $2.22 and $2.33 on volume of 254,234 shares traded. Analysts at Leerink have recently downgraded the company’s rating to "market perform" from "outperform". Shares of Amicus Therapeutics have fallen approximately 15.0 percent year-to-date.

ADVERTISEMENT

Find out more about Amicus Therapeutics including full access to the free equity report at:
www.RDInvesting.com/FOLD

Micrel, Inc. (NASDAQ:MCRL - News) shares declined 2.39 percent to close at $8.79 a share Friday. The stock traded between $8.74 and $9.23 on volume of 636,385 shares traded. Analysts at Sidoti have recently downgraded the company’s rating to "neutral" from "buy". Shares of Micrel have fallen approximately 7.0 percent year-to-date.

Find out more about Micrel including full access to the free equity report at:
www.RDInvesting.com/MCRL

Wi-LAN Inc. (NASDAQ:WILN - News)(TSX:WIN.TO - News) shares increased 2.62 percent to close at $3.13 a share Friday. The stock traded between $3.02 and $3.21 on volume of 679,220 shares traded. Analysts at CIBC have recently downgraded the company’s rating to "underperformer" from "outperformer". Shares of Wi-LAN have gained approximately 31.0 percent year-to-date.

Find out more about Wi-LAN including full access to the free equity report at:
www.RDInvesting.com/WILN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com